Quehuong Dong
President, CEO & DirectorDr. Quehuong Dong, Pharma.D, MBA, also known as Kathy, serves as President, Chief Executive Officer and Director at Electra Therapeutics, Inc. since October 2023. She is a seasoned biopharmaceutical executive with extensive experience in corporate development, business operations, portfolio management and product commercialization. She is Chief Operating Officer at STAR Therapeutics Inc. She oversees a broad range of responsibilities, including Corporate Development, Commercial, Portfolio Management and Technical Operations. She serves as Director of Neuron23, Inc. since June 2022. She served as the Chief Operating Officer of Star Therapeutics. since 2019. She had been Vice President of Commercial Development at True North Therapeutics, Inc. since April 05, 2017., where she led the launch and market development of numerous products in HBV and HCV, including SOVALDI and HARVONI. Prior to joining Star Therapeutics, she served as Vice President of Commercial Development at True North Therapeutics where she played a key role in building the market for the first approved therapy for the rare autoimmune disorder, cold agglutinin disease. Following True North’s acquisition by Bioverativ/Sanofi, she was Head of New Product Planning for the complement franchise at Sanofi. She has commercial experience within the biopharmaceutical industry. She served as a Director of HCV Marketing at Gilead Sciences where she was instrumental in developing and executing promotional strategies and tactical plans for Gilead’s HCV franchise, including the SOVALDI, HARVONI and EPCLUSA launches. Gilead Sciences. She holds a Doctor of Pharmacy and master’s in business administration from the University of New Mexico and completed a post-doctoral fellowship at Novartis Pharmaceuticals and Rutgers University.
Positions
- Company NameElectra Therapeutics, Inc.Stock CodeETRAPositionPresident, CEO & Director
